Hikma Pharmaceuticals PLC Asset Resilience Ratio
Hikma Pharmaceuticals PLC asset resilience ratio. Hikma Pharmaceuticals PLC (HIK) has an Asset Resilience Ratio of 0.49% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hikma Pharmaceuticals PLC (HIK) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hikma Pharmaceuticals PLC (2004–2024)
Asset resilience ratio of Hikma Pharmaceuticals PLC from 2004 to 2024. This chart shows how Hikma Pharmaceuticals PLC's Asset Resilience Ratio has changed over time. Read debt load of Hikma Pharmaceuticals PLC for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hikma Pharmaceuticals PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hikma Pharmaceuticals PLC balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX25.00 Million | 0.49% |
| Total Liquid Assets | GBX25.00 Million | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Hikma Pharmaceuticals PLC maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hikma Pharmaceuticals PLC Industry Peers by Asset Resilience Ratio
Compare Hikma Pharmaceuticals PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Hikma Pharmaceuticals PLC Asset Resilience Ratio by Year (2004–2024)
Hikma Pharmaceuticals PLC asset resilience ratio by year from 2004 to 2024. The table below shows the annual Asset Resilience Ratio data for Hikma Pharmaceuticals PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | GBX25.00 Million ≈ $3.04K |
GBX5.13 Billion ≈ $624.54K |
-0.03pp |
| 2023-12-31 | 0.51% | GBX24.00 Million ≈ $2.92K |
GBX4.68 Billion ≈ $569.42K |
+0.02pp |
| 2022-12-31 | 0.49% | GBX22.00 Million ≈ $2.68K |
GBX4.47 Billion ≈ $543.99K |
-0.06pp |
| 2021-12-31 | 0.55% | GBX24.00 Million ≈ $2.92K |
GBX4.37 Billion ≈ $531.95K |
-0.03pp |
| 2020-12-31 | 0.58% | GBX24.00 Million ≈ $2.92K |
GBX4.13 Billion ≈ $503.11K |
0.00pp |
| 2019-12-31 | 0.59% | GBX23.00 Million ≈ $2.80K |
GBX3.93 Billion ≈ $478.17K |
-0.02pp |
| 2018-12-31 | 0.60% | GBX21.00 Million ≈ $2.56K |
GBX3.50 Billion ≈ $425.48K |
-0.05pp |
| 2017-12-31 | 0.65% | GBX22.00 Million ≈ $2.68K |
GBX3.39 Billion ≈ $412.22K |
+0.19pp |
| 2016-12-31 | 0.46% | GBX20.00 Million ≈ $2.43K |
GBX4.36 Billion ≈ $530.85K |
-0.31pp |
| 2015-12-31 | 0.77% | GBX20.00 Million ≈ $2.43K |
GBX2.60 Billion ≈ $315.98K |
+0.41pp |
| 2014-12-31 | 0.36% | GBX8.00 Million ≈ $973.37 |
GBX2.25 Billion ≈ $273.88K |
-0.01pp |
| 2013-12-31 | 0.36% | GBX7.00 Million ≈ $851.70 |
GBX1.93 Billion ≈ $234.70K |
-0.28pp |
| 2012-12-31 | 0.64% | GBX11.04 Million ≈ $1.34K |
GBX1.73 Billion ≈ $210.50K |
+0.47pp |
| 2011-12-31 | 0.16% | GBX2.60 Million ≈ $315.74 |
GBX1.58 Billion ≈ $191.71K |
-0.16pp |
| 2010-12-31 | 0.32% | GBX3.57 Million ≈ $434.73 |
GBX1.12 Billion ≈ $135.76K |
+0.09pp |
| 2009-12-31 | 0.23% | GBX2.33 Million ≈ $283.98 |
GBX1.02 Billion ≈ $124.44K |
+0.14pp |
| 2008-12-31 | 0.08% | GBX819.00K ≈ $99.65 |
GBX966.46 Million ≈ $117.59K |
-0.54pp |
| 2007-12-31 | 0.63% | GBX5.63 Million ≈ $684.76 |
GBX894.04 Million ≈ $108.78K |
-0.46pp |
| 2006-12-31 | 1.09% | GBX5.34 Million ≈ $649.36 |
GBX488.36 Million ≈ $59.42K |
-0.19pp |
| 2005-12-31 | 1.29% | GBX5.12 Million ≈ $622.96 |
GBX397.96 Million ≈ $48.42K |
-1.83pp |
| 2004-12-31 | 3.12% | GBX7.69 Million ≈ $935.89 |
GBX246.48 Million ≈ $29.99K |
-- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more